| アブストラクト | BACKGROUND: There is a paucity of data on the initiation patterns of anticoagulants among older atrial fibrillation patients with and without chronic kidney disease (CKD). SETTING AND METHODS: We used the UK Clinical Practice Research Datalink (2010-2020) to conduct a retrospective cohort study to evaluate anticoagulant initiation patterns for older adults (>/=65 years) with CKD (N=18 421) and without CKD (N=41 901), categorised by severity of CKD: stages 3a, 3b and 4, and initiation dose by respective direct oral anticoagulant (DOAC). RESULTS: Over the study period, warfarin initiations sharply declined and were replaced by DOACs regardless of CKD status or stage. By 2020, patients with CKD were modestly more likely (8.8% difference) to initiate apixaban compared with those without CKD (58.8% vs 50.0%; p<0.01). Among patients with CKD, those with stages 3a and 3b CKD had higher apixaban initiations compared with stage 4 CKD (56.9% and 64.6% vs 52.9%, respectively; p<0.01). Conversely, patients with stage 4 CKD were over three times more likely to initiate warfarin (14.7%) compared with those with stage 3a (2.6%) and 3b (4.0%) CKD (p<0.01). Throughout the study period, there was a rise in the proportion of patients initiating the higher 10 mg daily dose for apixaban, with an increase of 20.6% (from 64.3% in 2013 to 84.9% in 2020; p value for trend <0.01) among patients without CKD, and 21.8% (53.1% to 74.9%; p<0.01), 24.4% (18.8% to 43.2%; p<0.01) and 18.5% (0.0% to 18.2%; p<0.01) among patients with stages 3a, 3b and 4 CKD, respectively. CONCLUSIONS AND RELEVANCE: Initiation of DOACs increased regardless of CKD status and stage, although with a reduced magnitude in severe CKD. Apixaban emerged as the preferred agent, with a secular trend towards the higher initiation dose in all subgroups. These findings illuminate evolving trends and priorities in anticoagulant preferences among patients with and without CKD. |
|---|
| ジャーナル名 | Open heart |
|---|
| Pubmed追加日 | 2024/2/2 |
|---|
| 投稿者 | Liaw, Julia; Liaw, Deborah; Dave, Chintan |
|---|
| 組織名 | Centers for Pharmacoepidemiology and Treatment Sciences, Rutgers University, New;Brunswick, New Jersey, USA.;Rutgers University, New Brunswick, New Jersey, USA.;University of South Florida Morsani College of Medicine, Tampa, Florida, USA.;Rutgers University, New Brunswick, New Jersey, USA cdave@ifh.rutgers.edu.;Department of Pharmacy Practice and Administration, Rutgers University, New |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38302138/ |
|---|
